Article Text

Download PDFPDF
A7.12 Micro-RNA signature in systemic lupus erythematosus
  1. I Duroux-Richard1,2,
  2. J Cuenca3,
  3. C Ponsolles1,2,
  4. A Badilla3,
  5. F González3,
  6. C Roubert4,
  7. R Areny5,
  8. R Chea6,
  9. J Pefaur6,
  10. C Jorgensen1,2,5,
  11. F Figueroa3,
  12. M Khoury3,
  13. F Apparailly1,2,5
  1. 1INSERM, U844, University Hospital Saint Eloi, Montpellier, France
  2. 2University of Medicine, Boulevard Henri IV, Montpellier, France
  3. 3University de Los Andes, Las Condes, Santiago, Chile
  4. 4Exploratory Unit, Sanofi R&D, Montpellier, France
  5. 5Hospital Félix Bulnes, Santiago, Chile
  6. 6Hospital José Joaquín Aguirre, Santiago Chile
  7. 7Clinical Department for Osteoarticular Diseases, University Hospital Lapeyronie, 371 Avenue Gaston Giraud, 34295 Montpellier, France


Background and objectives Several microRNAs are known to control the differentiation and function of B cells, that are considered key elements in the pathogenesis of systemic lupus erythematosus (SLE). However, a common miRNA signature has not emerged in SLE, since published data includes patients of variable ethnic background, type of disease and organ involvement. Moreover, published gene expression studies are often limited since they target only unfractionated, heterogeneous cell populations. Here, we aimed at identifying a miRNA-signature of purified B cells from renal and non renal severe (Bilag A) SLE patients of hispanic ethnic background, a population know to express severe disease.

Materials and methods Blood samples were obtained from healthy sex, age and ethnically matched controls (HC) with no history of autoimmune diseases and from SLE patients of chilean hispanic descent fulfilling SLICC and ACR criteria, with or without severe lupus nephritis (LN) (mean Bilag count respectively 17.8 and 16.8). Naive and memory B cells were sorted using CD27 surface marker. Total RNAs extraction, reverse transcription, and amplification steps were performed to fulfil quality and integrity criteria of the MIQE guidelines. The genome-wide miRNA expression study was perfomed using the TaqMan® Human MicroRNA Array Cards v3.0 (Applied Biosystems). Data were normalised using ExpressionSuite software (Life technologies) and analysed using RT2 profiler PCR array data analysis version 3.5 (Qiagen).

Results TLDA analyses of naive and memory B cells from HC and 2 subsets of SLE patients revealed two categories of miRNA-based signatures. The first signature represents miRNAs with potential as diagnostic biomarkers : 11 miRNAs discriminating all SLE patients from HC, and 8 miARNs discriminating patient subsets (SLE versus SLE-LN). The second signature identifies 13 miRNAs with therapeutic potential in lupus. Clustering analyses of TLDA datasets evidenced that the main differences in miRNA expression profilings between SLE patients were between naive and memory B cells, independently of disease severity. In all cases, whether the miRNA was up or down-regulated in memory B cells as compared with naive B cells in HC, this difference was abolished in SLE patients. Among these, we found miR-223 that was previously reported as deregulated in SLE, as well as in other autoimmune disorders and B cell leukaemia. Array data were further validated on individual samples (n = 6).

Conclusions Overall, the present work identified two types of miRNA-based signatures in circulating B cells isolated from Chilean SLE patients, providing promising biomarkers in molecular diagnostics for disease severity as well as potential new targets for therapeutic intervention in SLE.


  1. Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010; 32(6):815–27. doi: 10.1016/j.immuni.2010.06.001.

  2. Lécuyer E, Rakotobe S, Lengliné-Garnier H, et al. Segmented filamentous bacterium uses secondary and tertiary lymphoid tissues to induce gut IgA and specific T helper 17 cell responses. Immunity 2014; 40(4):608–20. doi: 10.1016/j.immuni.2014.03.009.

  3. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013; 72(6):844–50. doi: 10.1136/annrheumdis-2012-201612. Epub 2012 Jun 27.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.